

Mauro Di Ianni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5602782/publications.pdf>

Version: 2024-02-01

102
papers

4,050
citations

172457

29
h-index

118850

62
g-index

103
all docs

103
docs citations

103
times ranked

5938
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 939-949.	4.7	6
2	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. <i>Leukemia</i> , 2022, , .	7.2	2
3	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1199-1208.	5.2	34
4	NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models. <i>Bone Marrow Transplantation</i> , 2021, 56, 2019-2023.	2.4	2
5	NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status. <i>Frontiers in Oncology</i> , 2021, 11, 668573.	2.8	4
6	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6665.	4.1	11
7	Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2204-2210.	2.0	15
8	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020, 136, 171-182.	1.4	65
9	Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 7540-7553.	7.0	20
10	Adoptive Immunotherapy with Regulatory and Conventional T Cells in Haploidentical Transplantation Primes Dendritic Cells to Promote T Cell Alloreactivity in the Bone Marrow and Tolerance in the Periphery. <i>Blood</i> , 2019, 134, 3224-3224.	1.4	0
11	Regulatory T Cell Adoptive Immunotherapy Promotes B Cell Immunity after Haploidentical Transplantation. <i>Blood</i> , 2019, 134, 1917-1917.	1.4	0
12	Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2018, 143, 958-970.	5.1	32
13	Adoptive Immunotherapy with Regulatory and Conventional T-cells in Haploidentical T-cell Depleted Transplantation Protects from GvHD and Exerts GvL Effect. , 2018, , 43-54.		0
14	Secondary solid cancer following hematopoietic cell transplantation in patients with thalassemia major. <i>Bone Marrow Transplantation</i> , 2018, 53, 39-43.	2.4	13
15	IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. <i>Cell Death and Disease</i> , 2018, 9, 1160.	6.3	22
16	NOTCH and Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1825.	4.8	10
17	NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. <i>Frontiers in Oncology</i> , 2018, 8, 105.	2.8	20
18	NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 229.	2.8	55

#	ARTICLE	IF	CITATIONS
19	How Adoptive Immunotherapy with Conventional T and Regulatory T Cells Exerts a GvL Effect without GvHD, after Haploidentical Hematopoietic Transplantation. <i>Blood</i> , 2018, 132, 3333-3333.	1.4	3
20	Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Real Life Experience. <i>Blood</i> , 2018, 132, 5653-5653.	1.4	0
21	Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1225-1232.	2.4	12
22	Clinical-Gradeâ€œExpanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cellâ€œDependent Graft-versus-Leukemia Effect in Murine Models. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1847-1851.	2.0	24
23	Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT. <i>International Journal of Hematology</i> , 2017, 106, 860-864.	1.6	10
24	Ibrutinib Treatment of a Patient with Relapsing Chronic Lymphocytic Leukemia and Sustained Remission of Richter Syndrome. <i>Tumori</i> , 2017, 103, S37-S40.	1.1	4
25	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017, 8, 1844.	4.8	43
26	The NOTCH1/CD39 axis: a Treg trip-switch for GvHD. <i>Leukemia</i> , 2016, 30, 1931-1934.	7.2	13
27	How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocytopenic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2016, 128, 5472-5472.	1.4	0
28	The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. <i>British Journal of Haematology</i> , 2015, 170, 236-246.	2.5	32
29	Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. <i>Leukemia</i> , 2015, 29, 994-998.	7.2	14
30	Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. <i>Oncotarget</i> , 2015, 6, 16559-16572.	1.8	37
31	Patients with Unexplained Thrombosis Require a Prompt Investigation to Search a Chronic Myeloproliferative Neoplasm (MPN), Even If Platelet Count Is <600x10 ⁹ /L. Analysis on 129 Patients from Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2015, 126, 5181-5181.	1.4	0
32	Hematopoietic Stem/Progenitor Cells Express Myoglobin and Neuroglobin: Adaptation to Hypoxia or Prevention from Oxidative Stress?. <i>Stem Cells</i> , 2014, 32, 1267-1277.	3.2	8
33	A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 436-439.	7.2	32
34	â€œDesignedâ€œgrafts for HLA-haploidentical stem cell transplantation. <i>Blood</i> , 2014, 123, 967-973.	1.4	71
35	HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. <i>Blood</i> , 2014, 124, 638-644.	1.4	358
36	Tregs Suppress GvHD at the Periphery and Unleash the GvL Effect in the Bone Marrow. <i>Blood</i> , 2014, 124, 842-842.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Î³â€Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch downâ€regulation. International Journal of Cancer, 2013, 132, 1940-1953.	5.1	45
38	A novelNOTCH1PEST domain mutation in a case of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1780-1782.	1.3	8
39	Notch1 modulates mesenchymal stem cells mediated regulatory <scp>T</scp>â€cell induction. European Journal of Immunology, 2013, 43, 182-187.	2.9	59
40	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clinical and Experimental Immunology, 2013, 173, 195-206.	2.6	59
41	NOTCH and NF-Î²B interplay in chronic lymphocytic leukemia is independent of genetic lesion. International Journal of Hematology, 2013, 98, 153-157.	1.6	18
42	To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma. British Journal of Pharmacology, 2013, 169, 1652-1671.	5.4	38
43	A Novel, Non-canonical Splice Variant of the Ikaros Gene Is Aberrantly Expressed in B-cell Lymphoproliferative Disorders. PLoS ONE, 2013, 8, e68080.	2.5	12
44	HLA-Haploidentical Stem Cell Transplantation with Treg and Tcon Adoptive Immunotherapy promotes a Strong Graft-Versus-Leukemia Effect. Blood, 2013, 122, 907-907.	1.4	0
45	Effect Of Deferasirox On Reactive Species Of Oxygen (ROS) Production In Hematopoietic Stem Cells: Up Or Down?. Blood, 2013, 122, 1195-1195.	1.4	0
46	High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkinâ€™s lymphoma. Hematology, 2012, 17, 23-27.	1.5	18
47	The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes and Immunity, 2012, 13, 197-201.	4.1	35
48	High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clinical and Experimental Medicine, 2012, 12, 165-171.	3.6	15
49	T regulatory cell separation for clinical application. Transfusion and Apheresis Science, 2012, 47, 213-216.	1.0	38
50	Redox Signaling in Adult Stem Cell Biology: A New Target Controlling Pluripotency and Differentiation. What about Iron Chelators?.. Blood, 2012, 120, 2299-2299.	1.4	0
51	Tregs combined with mature donor T cells hasten immune reconstitution without triggering GvHD in HLA haploidentical transplantation. Arthritis Research and Therapy, 2011, 13, .	3.5	0
52	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood, 2011, 117, 3921-3928.	1.4	940
53	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 459-466.	1.7	40
54	Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study. American Journal of Hematology, 2011, 86, 914-917.	4.1	57

#	ARTICLE	IF	CITATIONS
55	Adoptive Immunotherapy with Tregs and Tcons Ensures Low TRM and a Low Incidence of Post Transplant Leukaemia Relapse After HLA Haploidentical Transplants for Acute Leukemia. <i>Blood</i> , 2011, 118, 154-154.	1.4	1
56	Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 85-90.	1.0	9
57	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. <i>Blood</i> , 2010, 116, 3907-3922.	1.4	100
58	Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL. <i>Blood</i> , 2010, 116, 2713-2723.	1.4	76
59	Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. <i>Blood</i> , 2010, 116, 5394-5402.	1.4	259
60	<i>NOTCH1</i> PEST domain mutation is an adverse prognostic factor in Bâ€œCLL. <i>British Journal of Haematology</i> , 2010, 151, 404-406.	2.5	97
61	Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1645-1652.	2.4	42
62	Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2009, 37, 1022-1029.	0.4	96
63	Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. <i>International Journal of Hematology</i> , 2009, 89, 76-79.	1.6	8
64	A new genetic lesion in Bâ€œCLL: a <i>NOTCH1</i> PEST domain mutation. <i>British Journal of Haematology</i> , 2009, 146, 689-691.	2.5	94
65	Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. <i>Clinical and Experimental Immunology</i> , 2009, 156, 246-253.	2.6	55
66	G-CSF-induced thrombocytopenia in a healthy donor. <i>Bone Marrow Transplantation</i> , 2009, 43, 263-264.	2.4	14
67	Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. <i>Cytotherapy</i> , 2009, 11, 86-96.	0.7	3
68	Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. <i>Blood</i> , 2009, 113, 856-865.	1.4	263
69	Adoptive Immunotherapy with Tregs Prevents GvHD and Favours Immune Reconstitution After HLA Haploidentical Transplants for Hematological Malignancies.. <i>Blood</i> , 2009, 114, 4-4.	1.4	14
70	Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. <i>Blood</i> , 2009, 114, 480-480.	1.4	0
71	Transformation by Retroviral Vectors of Bone Marrow-Derived Mesenchymal Cells Induces Mitochondria-Dependent cAMP-Sensitive Reactive Oxygen Species Production. <i>Stem Cells</i> , 2008, 26, 2843-2854.	3.2	25
72	MtDNA mutation associated with mitochondrial dysfunction in megakaryoblastic leukaemic cells. <i>Leukemia</i> , 2008, 22, 1938-1941.	7.2	12

#	ARTICLE	IF	CITATIONS
73	NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?. <i>Leukemia</i> , 2008, 22, 1459-1463.	7.2	19
74	Mesenchymal cells recruit and regulate T regulatory cells. <i>Experimental Hematology</i> , 2008, 36, 309-318.	0.4	286
75	Large-scale generation of human allodepleted anti-3rd party lymphocytes. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 106-112.	1.4	0
76	Comparison Between Adenoviral and Retroviral Vectors for the Transduction of the Thymidine Kinase PET Reporter Gene in Rat Mesenchymal Stem Cells. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1836-1844.	5.0	42
77	Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estrogenic treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 453-457.	1.0	3
78	CO-Culture with Mesenchymal Cells Modulates TGF-Beta/Smad And Mapk Pathways in T Regulatory Cells. <i>Blood</i> , 2008, 112, 676-676.	1.4	3
79	Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 923-930.	1.3	9
80	Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone. <i>Leukemia</i> , 2007, 21, 377-378.	7.2	4
81	Striking response to intrathecal liposomal cytarabine in a patient with meningeal myelomatosis. <i>British Journal of Haematology</i> , 2007, 138, 812-813.	2.5	11
82	Hematopoietic Stem Cell Transplantation from Alternative Donors for High-Risk Acute Leukemia: The Haploidentical Option. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 105-112.	1.3	21
83	Human Mesenchymal Cells Control T Regulatory Phenotypes and Functions.. <i>Blood</i> , 2007, 110, 2308-2308.	1.4	0
84	T Cell Pathway Deficiencies in Chronic Lymphocytic Leukemia: Partial Restoration with OKT3/IL-2 Activation.. <i>Blood</i> , 2007, 110, 4692-4692.	1.4	0
85	Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. <i>Leukemia and Lymphoma</i> , 2006, 47, 549-552.	1.3	8
86	Interleukin-7â€“Engineered Mesenchymal Cells: In Vitro Effects on Naive T-Cell Population. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1250-1260.	2.0	9
87	A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders. <i>Leukemia</i> , 2006, 20, 1895-1897.	7.2	7
88	Human Mesenchymal Cells Regulates Naive and Memory T Regulatory Cells.. <i>Blood</i> , 2006, 108, 1734-1734.	1.4	0
89	A Microelectronic DNA Chip Detects the V617F JAK-2 Allelic Ratio in Myeloproliferative Disorders.. <i>Blood</i> , 2006, 108, 3638-3638.	1.4	0
90	Engineering Mesenchymal Cells with Interleukin 7 Gene: In Vitro Effects on Naive T Cell Population.. <i>Blood</i> , 2006, 108, 5135-5135.	1.4	0

#	ARTICLE	IF	CITATIONS
91	B-chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by tumor necrosis factor β . <i>Leukemia Research</i> , 2005, 29, 829-839.	0.8	6
92	Interleukin 7-Engineered Stromal Cells: A New Approach for Hastening Naive T Cell Recruitment. <i>Human Gene Therapy</i> , 2005, 16, 752-764.	2.7	6
93	Graft engineering for allogeneic haploidentical stem cell transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 274-280.	1.4	18
94	Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. <i>Lancet Oncology</i> , The, 2004, 5, 64-65.	10.7	10
95	NeoR-Based Transduced T Lymphocytes Detected by Real-Time Quantitative Polymerase Chain Reaction. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 83-91.	1.8	4
96	Effect of trichostatin a and 5'-azacytidine on transgene reactivation in U937 transduced cells. <i>Pharmacological Research</i> , 2003, 48, 111-8.	7.1	9
97	Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID mice. <i>Cancer Gene Therapy</i> , 2002, 9, 756-761.	4.6	9
98	Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and enhanced green fluorescence protein genes in primary T lymphocytes. <i>British Journal of Haematology</i> , 2000, 110, 903-906.	2.5	5
99	T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. <i>Cancer Gene Therapy</i> , 2000, 7, 920-926.	4.6	15
100	In Vivo Demethylation of a MoMuLV Retroviral Vector Expressing the Herpes Simplex Thymidine Kinase Suicide Gene by 5'-azacytidine. <i>Stem Cells</i> , 2000, 18, 415-421.	3.2	3
101	T Lymphocyte Transduction with Herpes Simplex Virus Thymidine Kinase (HSV-tk) Gene: Comparison of Four Different Infection Protocols. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 645-652.	1.8	6
102	Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector. <i>Leukemia Research</i> , 1997, 21, 951-959.	0.8	9